Mira Kyivska

Launch of all-equity and fixed income ETFs: MFC support levels in focus

Launch of all-equity and fixed income ETFs: MFC support levels in focus
Manulife Financial slips 0.71% to C$61.13

Manulife Financial (MFC) stock is trading at C$61.13 after a modest decline in today’s session. The price currently sits below its key moving averages, hinting at near-term selling pressure but remains supported over the longer term.

MFC price prediction
24H -0.28%
CA$60.4
48H -0.1%
CA$60.51
7D -0.46%
CA$60.29
1M 1.16%
CA$61.27
3M 8.54%
CA$65.74
6M 5.32%
CA$63.79
12M 32.05%
CA$79.98
Current price: CA$60.57 -1.1000 1.78%
Closed 11/19
Daily range 60.19 Arrow from to Icon 61.68
Weekly range 60.19 Arrow from to Icon 63.20
Loading...

Highlights

  • Manulife Canada partnered with Sword to add AI-driven digital physiotherapy for disability claimants on its Group Benefits platform.
  • Manulife Investments expanded its ETF offerings with all-equity and all-fixed income portfolios targeting wider investor segments and incremental fee-based revenue.
  • Shares of Manulife closed down 0.71% to C$61.13, trading below key moving averages with technical indicators favoring further downside toward C$60.61 to C$61.65.

AI health initiative and ETF launches seen bolstering competitive edge

Manulife Canada’s partnership with Sword, as reported by Newswire, adds AI-enabled physiotherapy to its Group Benefits platform, aiming to enhance recovery experiences for eligible disability claimants through digital rehabilitation tools. This initiative may lower long-term benefits costs and improve the company’s competitive advantage in workplace insurance offerings. Separately, Manulife Investments expanded its ETF lineup with several new products, including All-Equity and All-Fixed Income portfolios, as reported by Aol, which could broaden its reach across investor segments and generate incremental fee-based revenue.

Manulife Financial Corporation asset chart
Manulife Financial Corporation price dynamics. Source: TradingView.

Intraday weakness persists as price meets key resistance and neutral momentum

MFC is trading below the MA-20 (C$61.58) and MA-50 (C$61.82) on the hourly chart but remains above the MA-200 (C$54.24). The Ichimoku Kijun at C$61.69 serves as immediate resistance, and support is identified near C$60.61. Momentum indicators point to persistent weakness: MACD and a neutral ADX reflect subdued trend strength, while RSI remains low at 43.92. Both CCI and Bull/Bear Power confirm intraday seller dominance, and Stoch RSI signals a strong sell. The Awesome Oscillator is neutral and does not reinforce either direction.

Downside risk elevated as tight range and resistance cap upside

For the next 2–3 trading days, MFC is expected to remain within a tight range between C$60.61 and C$61.65, representing the typical volatility band relative to current levels. The probability of an upward move is very low, while the likelihood of a further decline is high. A bullish scenario requires a break above resistance at C$61.69, whereas a bearish move could develop if support at C$60.61 fails, testing the lower end of the projected range.

Anton Kharitonov, expert at Traders Union, sees near-term weakness in Manulife Financial despite promising product and partnership news. He notes that technical indicators confirm ongoing selling, and the stock is capped by resistance around C$61.69. Kharitonov believes fresh initiatives may improve long-term fundamentals, but downside risk dominates the short-term outlook. "As long as MFC trades below C$61.69, the setup stays defensive and caution is warranted."

Previously it was reported that Manulife Financial was exhibiting a stable but technically weak trading pattern, with price action largely consolidating below resistance. The current update reinforces this view, as persistent near-term selling pressure and muted momentum indicate traders should monitor C$60.61 as the key support level for any signs of renewed downside.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.